Latest Global Distribution News

Australian Agricultural Company Limited (AACo) reported a 14% rise in operating profit to $58.4 million for FY25, driven by increased sales volumes and disciplined cost control despite challenging market conditions. The company also marked a significant reduction in statutory loss, signaling improved financial resilience.

RooLife Group Ltd (ASX:RLG) has secured its first $475,000 solar product order from India, marking a significant step in its global renewable energy expansion. This milestone underscores RLG’s unique model blending Chinese manufacturing with international marketing and distribution.

TZ Limited has secured its inaugural purchase order for data centre cabinet locking kits from Wesco Anixter, acting on behalf of Microsoft, marking a significant commercial milestone after a successful pilot phase.

Nova Eye Medical reported a 27% rise in Q3FY25 sales excluding China, driven by record US performance and a sharp reduction in glaucoma segment losses. The company confirmed FY25 revenue guidance and unveiled plans to expand its iTrack™ technology into ocular drug delivery.

Tissue Repair Limited reports initial patient enrolment in its pivotal Phase 3 trial for TR987®, alongside a robust 35% quarterly sales increase for its TR Pro+® product. The company is also advancing manufacturing and distribution strategies to support growth.

Nova Eye Medical reports a robust 39% increase in global sales driven by strong U.S. market demand and secures $6.6 million in fresh capital to fuel expansion and product development.

Enlitic reported a robust 41.1% increase in quarterly revenue alongside the completion of its strategic acquisition of Laitek, positioning the company for operational cash flow break-even by the end of 2025.

Universal Biosensors is expanding its handheld testing portfolio with the upcoming AQUASCOUT water sensor and growing sales of its FDA-approved Xprecia Prime blood coagulation device, targeting multi-billion-dollar markets.

Bioxyne Limited has raised its FY2025 revenue forecast to $25 million, driven by a remarkable 267% increase in first-half revenue and strong momentum from its subsidiary Breathe Life Sciences.

First Graphene Limited strengthens its financial footing with a UK R&D tax rebate and expands its global footprint through new distribution agreements in India and Brazil.